Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Ritter Pharmaceuticals Inc (RTTR) USD0.001

Sell:$0.27 Buy:$0.33 Change: $0.014 (4.38%)
NASDAQ:1.34%
Market closed |  Prices as at close on 11 October 2019 | Switch to live prices |
Sell:$0.27
Buy:$0.33
Change: $0.014 (4.38%)
Market closed |  Prices as at close on 11 October 2019 | Switch to live prices |
Sell:$0.27
Buy:$0.33
Change: $0.014 (4.38%)
Market closed |  Prices as at close on 11 October 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Ritter Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company's segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient's health. The Company's compound, RP-G28, is under development for the treatment of lactose intolerance. The Company has completed a Phase IIa clinical trial of its product candidate, RP-G28, an orally administered oligosaccharide. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. The Company has not generated any revenues.

Contact details

Address:
1880 Century Park E Ste 1000
LOS ANGELES
90067-1623
United States
Telephone:
+1 (310) 2031000
Website:
www.ritterpharmaceuticals.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
RTTR
ISIN:
US7678363075
Market cap:
$2.88 million
Shares in issue:
9.43 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Ira Ritter
    Executive Chairman of the Board, Chief Strategic Officer
  • Andrew Ritter
    President, Chief Executive Officer, Founder, Director
  • John Beck
    Chief Financial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.